Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT01130805 Completed - Gastric Cancer Clinical Trials

A Study of Pazopanib With CAPEOX in AGC Patients

Start date: December 2010
Phase: Phase 2
Study type: Interventional

In order to improve survival of metastatic gastric cancer patients, we plan to to conduct a phase II trial of CapeOx with 800 mg once-daily pazopanib as a first-line chemotherapy in metastatic gastric cancer patients.

NCT ID: NCT01130337 Completed - Gastric Cancer Clinical Trials

A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer. The combination of Xeloda (orally, 1000 mg/m2 on day 1-14 of every cycle) and Herceptin (intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1-14 of every cycle) will be administered for three cycles prior to surgery to resect the tumor. If complete resection, R0 or microscopic residual tumor R1 is achieved, patients will continue with three cycles of XELOX and Herceptin and then for completion of 12 months treatment with Herceptin alone. Oxaliplatin will be administered intravenously at a dose of 130 mg/m2 on day 1 in every cycle. The anticipated time on study drug will be 12 months.

NCT ID: NCT01123876 Completed - Gastric Cancer Clinical Trials

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Start date: March 2010
Phase: Phase 1
Study type: Interventional

Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.

NCT ID: NCT01123811 Completed - Clinical trials for Adenocarcinoma of Stomach or Esophagogastric Junction

Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer

GC-CIF-2005
Start date: May 2006
Phase: Phase 2
Study type: Interventional

Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in gastric cancer , the present clinical study to evaluate the overall response rate, the time to progression and the overall survival of the combined treatment of cetuximab and irinotecan and 5-FU in patients with esophagogastric cancer is urgently needed.

NCT ID: NCT01099527 Completed - Clinical trials for Metastatic Gastric Cancer

A Trial of RAD001/Capecitabine in Refractory Gastric Cancer

Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory gastric cancer patients.

NCT ID: NCT01099085 Completed - Gastric Cancer Clinical Trials

Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients

Start date: February 2009
Phase: Phase 3
Study type: Interventional

Based on antitumor activity of statin, we designed a phase III study of capecitabine/CDDP chemotherapy plus a low-dose simvastatin that is equivalent to cardiovascular dose in advanced gastric cancer patients.

NCT ID: NCT01084330 Completed - Clinical trials for Advanced Gastric Cancer

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Start date: April 2010
Phase: Phase 2
Study type: Interventional

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

NCT ID: NCT01073046 Completed - Gastric Cancer Clinical Trials

Gastric Decompression After Sub-total Gastrectomy

Start date: January 2010
Phase: N/A
Study type: Observational

The purpose of this study is to test the utility of the nasogastric tube, which is used to decompress and as "guardian" of gastro-jejunal anastomosis, in patients undergoing distal subtotal gastrectomy for gastric cancer with reconstruction according to Billroth II or according Roux.

NCT ID: NCT01065688 Completed - Gastric Cancer Clinical Trials

A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer

Start date: January 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the quality of life (QOL) after Billroth-I reconstruction (B-I) following distal gastrectomy, compared with Roux-en Y reconstruction (R-Y) in patients with gastric cancer.

NCT ID: NCT01063517 Completed - Gastric Cancer Clinical Trials

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Start date: February 2, 2010
Phase: Phase 2
Study type: Interventional

To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy.